Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 53

Sort by

Sort Order Select

Journal Articles

Venous Thromboembolism in Hematopoietic Stem Cell Transplantation

Jodi Chiu, Brianna Ananthan, Matthew Lawrence, Mohamed Aly, Dhuvaraha Srikrishnaraj, Madeleine Weichel, Uday Deotare, Anargyros Xenocostas, Alejandro Lazo-Langner

Blood (2023) 142 (Supplement 1): 4022.

https://doi.org/10.1182/blood-2023-180737

Published: 2023

Journal Articles

Development of a Combined Risk Assessment Model for Venous Thromboembolism and Bleeding in Hematopoietic Stem Cell Transplantation Patients

Jodi Chiu, Uday Deotare, Anargyros Xenocostas, Alejandro Lazo-Langner

Blood (2023) 142 (Supplement 1): 1273.

https://doi.org/10.1182/blood-2023-180776

Published: 2023

Journal Articles

Risk Factor Analysis for Second Treatment-Free Remission Failure from the Canadian TKI Discontinuation (TRAD) Trial in CML Patients: Treatment-Free Remission Accomplished By Dasatinib

Maria Agustina Perusini, Eshetu G. Atenafu, Donna L. Forrest, Bence-Bruckler Isabelle, Lynn Savoie, Mary-Margaret Keating, Lambert Busque, Robert Delage, Anargyros Xenocostas, Elena Liew, Pierre Laneuville, Kristjan Paulson, Tracy L. Stockley, Jeffrey H. Lipton, Brian Leber, Dennis Dong Hwan Kim

Blood (2022) 140 (Supplement 1): 6778–6779.

https://doi.org/10.1182/blood-2022-167581

Published: 2022

Journal Articles

Update of Multicenter, Retrospective Evaluation of Overall Response and Failure Free Survival Following Ruxolitinib Therapy for Heavily Pre-Treated Chronic Gvhd Patients with Steroid-Failure: A Proposal of Risk Score Model for Failure-Free Survival

Jennifer White, Mohamed Elemary, Swe Mar Linn, Igor Novitzky-Basso, Anargyros Xenocostas, Nada Hamad, Samantha Culos, Sui Tan, Arjun Law, Rajat Kumar, Jonas Mattsson, Dennis Dong Hwan Kim, Sr.

Blood (2021) 138 (Supplement 1): 3905.

https://doi.org/10.1182/blood-2021-148859

Published: 2021

Journal Articles

Outcomes of Single Versus Tandem Hematopoietic Stem Cell Autologous Transplant in High-Risk Myeloma Patients: A Single-Center Experience

Shona Philip, Mina Dehghani, Lenicio Siqueira, Anthony Quint, Selay Lam, Chai Wye Phua, Anargyros Xenocostas, Uday Deotare, Martha L Louzada

Blood (2021) 138 (Supplement 1): 4893.

https://doi.org/10.1182/blood-2021-149602

Published: 2021

Journal Articles

Outcomes of Tandem Hematopoietic Stem Cell Autologous Transplant in High-Risk Myeloma Patients: A Single-Center Experience

Shona Philip, Selay Lam, Chai Wye Phua, Martha L Louzada, Anargyros Xenocostas, Uday Deotare

Blood (2021) 138 (Supplement 1): 4901.

https://doi.org/10.1182/blood-2021-153321

Published: 2021

Journal Articles

Outcomes of Maintenance Treatment Post Autologous Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma Patients: A Canadian Single Center Experience

Mina Dehghani, Shona Philip, Anthony Quint, Lenicio Siqueira, Selay Lam, Chai Wye Phua, Anargyros Xenocostas, Uday Deotare, Martha L Louzada

Blood (2021) 138 (Supplement 1): 2710.

https://doi.org/10.1182/blood-2021-153876

Published: 2021

Journal Articles

Propensity Score Matching Analysis Comparing Ruxolitinib Vs Historical Controls in 2 nd Line or Beyond Treatment for Chronic Gvhd after Therapy Failure

Igor Novitzky-Basso, Swe Mar Linn, Jennifer White, Mohamed Elemary, Anargyros Xenocostas, Nada Hamad, Sui Tan, Samantha Culos, Arjun Law, Dennis Dong Hwan Kim

Blood (2021) 138 (Supplement 1): 1805.

https://doi.org/10.1182/blood-2021-151683

Published: 2021

Journal Articles

A Real-World Canadian Experience of Asciminib Use in Chronic Myeloid Leukemia (CML) Patients Who Failed Multiple Lines of Tyrosine Kinase Inhibitor (TKI) Therapy

Fatima Khadadah, Anargyros Xenocostas, Lambert Busque, Kareem Jamani, Sonia Cerquozzi, Philip Kuruvilla, Brian Leber, Rayan Kaedbey, Sarit Assouline, Dennis Dong Hwan Kim

Blood (2021) 138 (Supplement 1): 3610.

https://doi.org/10.1182/blood-2021-149588

Published: 2021

Journal Articles

Risk of Major Bleeding with Ibrutinib in Patients with Thrombocytopenia - a Retrospective Single-Center Canadian Study

Mina Dehghani, Taylor Dear, Anthony Quint, Martha L Louzada, Selay Lam, Chai Wye Phua, Joy Mangel, Kang Howson-Jan, Michael J. Kovacs, Alejandro lazo-Langer, Anargyros Xenocostas, Cyrus C. Hsia

Blood (2021) 138 (Supplement 1): 4682.

https://doi.org/10.1182/blood-2021-153719

Published: 2021

Journal Articles

Excellent Outcomes in Patients with Primary and Secondary Central Nervous System Lymphoma Undergoing Autologous Stem Cell Transplantation Using a Rituximab, Busulfan, Melphalan, Thiotepa Conditioning Regimen

Shona Philip, BSc, MD, Adrienne Fulford, NP,MSN, Selay Lam, MDBSc,FRCPC, Chai Wye Phua, MD FRCPC, Joy Mangel, MD FRCPC, Kang Howson-Jan, MD FRCPC, Brandon Dorland, NP, MSN, Karen Atkinson, NP, MSN, Anargyros Xenocostas, MD FRCPC, Uday Deotare, MBBS, MD DM

Blood (2020) 136 (Supplement 1): 2.

https://doi.org/10.1182/blood-2020-139635

Published: 2020

Journal Articles

Identifying Myeloid Mutations By NGS in Patients with Unexplained Erythrocytosis

Eri Kawata, MDPhD, Anargyros Xenocostas, MD FRCPC, Cyrus C. Hsia, MDBSc,FRCPC, Alejandro Lazo-Langner, MDMSc, Michael Levy, PhD, Stephanie Santos, Hanxin Lin, PhD, Chris Howlett, Bekim Sadikovic, PhD DABMGG, FACMG, Ian Chin-Yee, MD FRCPC

Blood (2020) 136 (Supplement 1): 47.

https://doi.org/10.1182/blood-2020-138654

Published: 2020

Journal Articles

BCR-ABL1 Transcript Doubling Time after Imatinib Discontinuation for Treatment-Free Remission in Chronic Myeloid Leukemia in Chronic Phase: Predictor for Treatment-Free Remission Failure

Dennis Dong Hwan Kim, MD, Igor Nicolas Novitzky-Basso, MDPhDMRCP,FRCPath, Taehyung Kim, MSc, Eshetu G Atenafu, M.Sc., P.Stat, Donna L. Forrest, MD, Lynn Savoie, MD, Isabelle Bence-Bruckler, MD, Mary-Margaret Keating, MD FRCPC, Lambert Busque, MD, Robert Delage, MD, Anargyros Xenocostas, MD FRCPC, Elena Liew, MDBSc,FRCPC, Kristjan Paulson, MD, Tracy L. Stockley, PhD FCCMG, FACMG, Pierre Laneuville, MD FRCPC, Jeffrey H. Lipton, MD PhD, Suzanne Kamel-Reid, BA, MA, PhD FACMG, Brian Leber, MD

Blood (2020) 136 (Supplement 1): 40–41.

https://doi.org/10.1182/blood-2020-136162

Published: 2020

Journal Articles

Optimal Duration of Imatinib Treatment / Deep Molecular Response for Treatment-Free Remission after Imatinib Discontinuation from a Canadian Tyrosine Kinase Inhibitor Discontinuation Trial

Dennis Dong Hwan Kim, MD, Igor Nicolas Novitzky-Basso, MDPhDMRCP,FRCPath, Taehyung Kim, MSc, Eshetu G Atenafu, M.Sc., P.Stat, Lynn Savoie, MD, Isabelle Bence-Bruckler, MD, Donna L. Forrest, MD, Lambert Busque, MD, Robert Delage, MD, Anargyros Xenocostas, MD FRCPC, Mary-Margaret Keating, MD FRCPC, Elena Liew, MDBSc,FRCPC, Kristjan Paulson, MD, Tracy L. Stockley, PhD FCCMG, FACMG, Pierre Laneuville, MD FRCPC, Jeffrey H. Lipton, MD PhD, Suzanne Kamel-Reid, BA, MA, PhD FACMG, Brian Leber, MD

Blood (2020) 136 (Supplement 1): 54–55.

https://doi.org/10.1182/blood-2020-136163

Published: 2020

Journal Articles

Efficacy of Oral Ribavirin in Respiratory Syncytial Virus Infection in Hematopoietic Stem Cell Transplant Patients: A Single-Centre Experience

Shona Philip, BSc, MD, Adrienne Fulford, NP,MSN, Krista Biederman, BScPhm, Brandon Dorland, NP, MSN, Anargyros Xenocostas, MD FRCPC, Uday Deotare, MBBS, MD DM

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-142888

Published: 2020

Journal Articles

Reducing Cytogenetic Testing in the Era of Next Generation Sequencing (NGS); Are We Choosing Wisely?

Eri Kawata, MDPhD, Benjamin Hedley, PhD, Benjamin Chin-Yee, MD, Anargyros Xenocostas, MD FRCPC, Alejandro Lazo-Langner, MDMSc, Cyrus C. Hsia, MDBSc,FRCPC, Kang Howson-Jan, MD FRCPC, Ping Yang, PhD DABMGG, Michael Levy, PhD, Stephanie Santos, Chris Howlett, Hanxin Lin, PhD, Bekim Sadikovic, PhD DABMGG, FACMG, Ian Chin-Yee, MD FRCPC

Blood (2020) 136 (Supplement 1): 12–13.

https://doi.org/10.1182/blood-2020-138667

Published: 2020

Journal Articles

Comprehensive Analysis of Hematological Parameter Changes after TKI Discontinuation for Treatment-Free Remission Attempt

Georgina S. Daher-Reyes, MD, Isabelle Bence-Bruckler, MD, Lambert Busque, MD, Donna L. Forrest, MD, Lynn Savoie, MD, Mary-Margaret Keating, MD, Robert Delage, MD, Anargyros Xenocostas, MD FRCPC, Elena Liew, MDBSc,FRCPC, Pierre Laneuville, MD FRCPC, Kristjan Paulson, MD, Jeffrey H. Lipton, MD PhD, Suzanne Kamel-Reid, BA, MA, PhD FACMG, Brian Leber, MD, Dennis Dong Hwan Kim, MD PhD

Blood (2019) 134 (Supplement_1): 1653.

https://doi.org/10.1182/blood-2019-131599

Published: 2019

Journal Articles

Reevaluating the Role of Cytogenetic Testing in Patients with Suspected Myelodysplastic Syndrome in the Era of Next Generation Sequencing

Eri Kawata, MD PhD, Anargyros Xenocostas, MD FRCPC, Cyrus C. Hsia, MDBSc,FRCPC, Alejandro Lazo-Langner, MD MSc, Kang Howson-Jan, MD FRCPC, Uday Deotare, MBBS, MD DM, Lalit Saini, MD, Benjamin Hedley, PhD, Ping Yang, PhD DABMGG, Michael Levy, PhD, Hanxin Lin, PhD, Bekim Sadikovic, PhD DABMGG, FACMG, Ian Chin-Yee, MD FRCPC

Blood (2019) 134 (Supplement_1): 3438.

https://doi.org/10.1182/blood-2019-128507

Published: 2019

Journal Articles

The Canadian Tyrosine Kinase Inhibitor Discontinuation Trial with Imatinib Discontinuation As a First Attempt and with Dasatinib Discontinuation As a Second Attempt of Treatment-Free Remission: Results of 4 Years of Follow-up

Dennis Dong Hwan Kim, MD, Isabelle Bence-Bruckler, MD, Lambert Busque, MD, Donna L. Forrest, MD, Lynn Savoie, MD, Mary-Margaret Keating, MD, Robert Delage, MD, Anargyros Xenocostas, MD FRCPC, Elena Liew, MDBSc,FRCPC, Pierre Laneuville, MD FRCPC, Kristjan Paulson, MD, Jeffrey H. Lipton, MD PhD, Suzanne Kamel-Reid, BA, MA, PhD FACMG, Brian Leber, MD

Blood (2019) 134 (Supplement_1): 1644.

https://doi.org/10.1182/blood-2019-128283

Published: 2019

Journal Articles

BCR-ABL1 qPCR-Based Doubling Time within the First 6 Months after Imatinib Discontinuation Is a Predictive of Successful TKI Treatment-Free Remission

Blood (2019) 134 (Supplement_1): 2933.

https://doi.org/10.1182/blood-2019-131454

Published: 2019

NARROW

Venous Thromboembolism in Hematopoietic Stem Cell Transplantation

Development of a Combined Risk Assessment Model for Venous Thromboembolism and Bleeding in Hematopoietic Stem Cell Transplantation Patients

Risk Factor Analysis for Second Treatment-Free Remission Failure from the Canadian TKI Discontinuation (TRAD) Trial in CML Patients: Treatment-Free Remission Accomplished By Dasatinib

Update of Multicenter, Retrospective Evaluation of Overall Response and Failure Free Survival Following Ruxolitinib Therapy for Heavily Pre-Treated Chronic Gvhd Patients with Steroid-Failure: A Proposal of Risk Score Model for Failure-Free Survival

Outcomes of Single Versus Tandem Hematopoietic Stem Cell Autologous Transplant in High-Risk Myeloma Patients: A Single-Center Experience

Outcomes of Tandem Hematopoietic Stem Cell Autologous Transplant in High-Risk Myeloma Patients: A Single-Center Experience

Outcomes of Maintenance Treatment Post Autologous Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma Patients: A Canadian Single Center Experience

Propensity Score Matching Analysis Comparing Ruxolitinib Vs Historical Controls in 2 nd Line or Beyond Treatment for Chronic Gvhd after Therapy Failure

A Real-World Canadian Experience of Asciminib Use in Chronic Myeloid Leukemia (CML) Patients Who Failed Multiple Lines of Tyrosine Kinase Inhibitor (TKI) Therapy

Risk of Major Bleeding with Ibrutinib in Patients with Thrombocytopenia - a Retrospective Single-Center Canadian Study

Excellent Outcomes in Patients with Primary and Secondary Central Nervous System Lymphoma Undergoing Autologous Stem Cell Transplantation Using a Rituximab, Busulfan, Melphalan, Thiotepa Conditioning Regimen

Identifying Myeloid Mutations By NGS in Patients with Unexplained Erythrocytosis

BCR-ABL1 Transcript Doubling Time after Imatinib Discontinuation for Treatment-Free Remission in Chronic Myeloid Leukemia in Chronic Phase: Predictor for Treatment-Free Remission Failure

Optimal Duration of Imatinib Treatment / Deep Molecular Response for Treatment-Free Remission after Imatinib Discontinuation from a Canadian Tyrosine Kinase Inhibitor Discontinuation Trial

Efficacy of Oral Ribavirin in Respiratory Syncytial Virus Infection in Hematopoietic Stem Cell Transplant Patients: A Single-Centre Experience

Reducing Cytogenetic Testing in the Era of Next Generation Sequencing (NGS); Are We Choosing Wisely?

Comprehensive Analysis of Hematological Parameter Changes after TKI Discontinuation for Treatment-Free Remission Attempt

Reevaluating the Role of Cytogenetic Testing in Patients with Suspected Myelodysplastic Syndrome in the Era of Next Generation Sequencing

The Canadian Tyrosine Kinase Inhibitor Discontinuation Trial with Imatinib Discontinuation As a First Attempt and with Dasatinib Discontinuation As a Second Attempt of Treatment-Free Remission: Results of 4 Years of Follow-up

BCR-ABL1 qPCR-Based Doubling Time within the First 6 Months after Imatinib Discontinuation Is a Predictive of Successful TKI Treatment-Free Remission

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only